A putative therapeutic target in primary biliary cholangitis: Q495T6

Ablatotech Signals reports today on a putative therapeutic target — Q495T6 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in primary biliary cholangitis.

# Signals Article: Exploring the Putative Target Q495T6 for Primary Biliary Cholangitis

Background

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the bile ducts, leading to cholestasis and, ultimately, liver failure. Current treatment options are limited and primarily focus on managing symptoms and slowing disease progression. There is a pressing need for novel therapeutic targets that could offer more effective interventions. The protein encoded by UniProt entry Q495T6 has emerged as a putative target that warrants further investigation in the context of PBC.

Data-mining rationale

The identification of Q495T6 as a putative target for PBC was achieved through a comprehensive cross-referencing of UniProt's reviewed human entries associated with "primary biliary cholangitis" against 11 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate Q495T6 appeared in several expression-profiling studies, yet it lacks any registered Phase 1 or higher clinical program, suggesting an opportunity for further exploration of its therapeutic potential. The datasets used in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, indicating that a re-analysis could provide more robust insights.

Why prior analyses may have missed this

Prior analyses may have overlooked the significance of Q495T6 due to several factors. Many of the GEO datasets were generated using older statistical methodologies that may not have adequately controlled for multiple testing, potentially obscuring the identification of differentially expressed genes. Additionally, the complex pathophysiology of PBC, involving immune-mediated destruction of bile ducts, may have diluted the signal for specific targets in earlier studies. The absence of a clinical program for Q495T6 further suggests that its therapeutic potential has not been fully explored in the context of PBC.

Reasoning for further validation

To substantiate the potential role of Q495T6 in primary biliary cholangitis, several experimental approaches are recommended:

**Re-analyze the matched GEO datasets**: Utilize the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater statistical rigor.
**Validate top differentially-expressed genes**: Conduct quantitative PCR (qPCR) validation of the top differentially expressed genes identified in the re-analysis using an independent cohort to confirm their relevance in PBC.
**Check tissue specificity**: Investigate the tissue specificity of Q495T6 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its potential as a therapeutic target.
**Explore pathway context**: Employ STRING or OmniPath databases to explore the biological pathways associated with Q495T6, providing context for its role in PBC pathogenesis.
**Assess druggability**: If Q495T6 is validated as a relevant target, evaluate its druggability using databases such as DGIdb and ChEMBL to identify potential small molecules or compounds that could be developed into therapeutics.

References